Shares of Viking Therapeutics VKTX rose about 36% on Tuesday after the company announced positive data from a maintenance dosing study evaluating its lead obesity candidate, VK2735. Results showed that participants preserved most of their weight loss from the induction phase even when dosing frequency was materially reduced. VKTX Stock's Performance Year to date, the company's shares have gained 16% compared with the industry's 7% growth.Zacks Investment Research Image Source: Zacks Investment Research Viking's Maintenance Study Used a Two-Phase Dosing Design The maintenance study was designed to examine whether weight loss achieved with weekly VK2735 treatment could be sustained after reducing the frequency of dosing.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.